相关实验视频
Updated: Jun 28, 2025

08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
7.2K
索拉菲尼布通过阻断LOXL2-介导的血管化来抑制后侧纵向带的骨化
Longqing Wang1, Wenhao Jiang2, Siyuan Zhao3
1Spine Center, Department of Orthopaedics, Shanghai Changzheng Hospital, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, PR China.
Bone research
|April 9, 2024
概括
后长度带骨化 (OPLL) 涉及带细胞变得像骨一样. LOXL2通过HIF1A途径驱动这种情况,但索拉芬尼通过向血管化来有效抑制OPLL的进展.
科学领域:
- 生物医学研究的研究.
- 分子生物学分子生物学
- 病理学 病理学 病理学
背景情况:
- 后长度带骨化 (OPLL) 是一种退行性疾病,导致脊柱不运动和神经压缩.
- 了解OPLL的细胞和分子机制对于开发有效治疗方法至关重要.
研究的目的:
- 在单细胞分辨率下阐明OPLL的分子和细胞进化.
- 确定OPLL的关键调节者和潜在的治疗点.
主要方法:
- 在OPLL组织中大量和单细胞RNA测序.
- 带干细胞分化的体外和体内研究.
- 对于LOXL2.2.的功能增益和丧失研究.
- 在OPLL动物模型中评估索拉芬尼的疗效.
主要成果:
- 在OPLL期间,带干细胞可以采用内皮细胞类的表型.
- LOXL2作为一个关键的调节器,通过HIF1A通路促进内皮状分化.
- 索拉芬尼抑制了LOXL2介导的血管形态发生,并在动物模型中显著降低了OPLL的进展,而不会影响正常的骨质.
结论:
- LOXL2是通过非酶性调节血管化的OPLL病变的关键调解者.
- 索拉费尼布通过破坏血管化-骨质生成合,显示出对OPLL的治疗潜力.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K

